Download PDF
Horm Metab Res 2024; 56(12): 839-844
DOI: 10.1055/a-2411-9426
Review

Denosumab for Management of Hypercalcemia in Primary Hyperparathyroidism

Yihan Zhao
1   Department of Endocrinology and Metabolism, Peking University Peopleʼs Hospital, Beijing, China (Ringgold ID: RIN71185)
,
Fang Zhang
1   Department of Endocrinology and Metabolism, Peking University Peopleʼs Hospital, Beijing, China (Ringgold ID: RIN71185)
,
Simin Zhang
1   Department of Endocrinology and Metabolism, Peking University Peopleʼs Hospital, Beijing, China (Ringgold ID: RIN71185)
,
Xiaona Zhang
1   Department of Endocrinology and Metabolism, Peking University Peopleʼs Hospital, Beijing, China (Ringgold ID: RIN71185)
,
Leili Gao
1   Department of Endocrinology and Metabolism, Peking University Peopleʼs Hospital, Beijing, China (Ringgold ID: RIN71185)
,
Qian Ren
1   Department of Endocrinology and Metabolism, Peking University Peopleʼs Hospital, Beijing, China (Ringgold ID: RIN71185)
,
Xueyao Han
1   Department of Endocrinology and Metabolism, Peking University Peopleʼs Hospital, Beijing, China (Ringgold ID: RIN71185)
,
Linong Ji
1   Department of Endocrinology and Metabolism, Peking University Peopleʼs Hospital, Beijing, China (Ringgold ID: RIN71185)
› Author AffiliationsSupported by: Research and Development Fund of Peking University Peopleʼs Hospital RDL2022-20
› Further Information
Also available at
   Permissions and Reprints

Abstract

Denosumab is a completely human monoclonal high-affinity antibody that binds to the nuclear factor kappa-B ligand (RANKL) and is widely used to treat osteoporosis. Furthermore, it can potentially lower serum calcium levels by inhibiting osteoclast activation and preventing bone calcium from being released into the blood. This review aimed to provide evidence of the efficacy and safety of denosumab in treating hypercalcemia in primary hyperparathyroidism (PHPT). PubMed and the Cochrane Library were searched for published studies that described denosumab for hypercalcemia management in PHPT. Data were extracted by two independent investigators and analyzed using SPSS 23. The risk of bias was assessed by NIH Quality Assessment Tool. In total, 161 patients with PHPT from 18 studies were included in this review. The average age was 61 (47–72) years and the highest serum calcium was 3.76 (3.11–4.20) mmol/l. We found that denosumab can effectively reduce the serum calcium level by a median reduction of 0.5 mmol/l within 3 days. Significant reduction was maintained for 14 days. The serum calcium-lowering effect weakened after one month. In conclusion, denosumab has a potential clinical value in treating hypercalcemia in patients with PHPT.

Keywords

denosumab - calcium homeostasis - hypercalcemia - hyperparathyroidism

Supplementary Material



Publication History

Received: 02 July 2024

Accepted after revision: 01 September 2024

Article published online:
11 October 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Walker MD, Silverberg SJ. Primary hyperparathyroidism. Nat Rev Endocrinol 2018; 14: 115-125
    CrossrefPubMedSearch in Google Scholar
  • 2 Ziegler R. Hypercalcemic crisis. J Am Soc Nephrol 2001; 12: S3-S9
    CrossrefPubMedSearch in Google Scholar
  • 3 Wilhelm SM, Wang TS, Ruan DT. et al. The American association of endocrine surgeons guidelines for definitive management of primary hyperparathyroidism. JAMA Surg 2016; 151: 959-968
    CrossrefPubMedSearch in Google Scholar
  • 4 Pappachan JM, Lahart IM, Viswanath AK. et al. Parathyroidectomy for adults with primary hyperparathyroidism. Cochrane Database Syst Rev 2023; 3: Cd013035
    PubMedSearch in Google Scholar
  • 5 Cummings SR, San Martin J, McClung MR. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756-765
    CrossrefPubMedSearch in Google Scholar
  • 6 Kendler DL, Cosman F, Stad RK. et al. Denosumab in the treatment of osteoporosis: 10 years later: a narrative review. Adv Ther 2022; 39: 58-74
    CrossrefPubMedSearch in Google Scholar
  • 7 Bollerslev J, Rejnmark L, Zahn A. et al. European expert consensus on practical management of specific aspects of parathyroid disorders in adults and in pregnancy: recommendations of the ESE educational program of parathyroid disorders. Eur J Endocrinol 2022; 186: R33-R63
    CrossrefPubMedSearch in Google Scholar
  • 8 Eller-Vainicher C, Palmieri S, Cairoli E. et al. Protective effect of denosumab on bone in older women with primary hyperparathyroidism. J Am Geriatr Soc 2018; 66: 518-524
    CrossrefPubMedSearch in Google Scholar
  • 9 Eremkina A, Krupinova J, Dobreva E. et al. Denosumab for management of severe hypercalcemia in primary hyperparathyroidism. Endocr Connect 2020; 9: 1019-1027
    CrossrefPubMedSearch in Google Scholar
  • 10 Gronskaya S, Belaya Z, Rozhinskaya L. et al. Denosumab for osteoporosis in patients with primary hyperparathyroidism and mild-to-moderate renal insufficiency. Endocrine 2023; 81: 368-378
    CrossrefPubMedSearch in Google Scholar
  • 11 Leere JS, Karmisholt J, Robaczyk M. et al. Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2020; 8: 407-417
    CrossrefPubMedSearch in Google Scholar
  • 12 Miyaoka D, Imanishi Y, Kato E. et al. Effects of denosumab as compared with parathyroidectomy regarding calcium, renal, and bone involvement in osteoporotic patients with primary hyperparathyroidism. Endocrine 2020; 69: 642-649
    CrossrefPubMedSearch in Google Scholar
  • 13 Çalapkulu M, Gul OO, Cander S. et al. Control of refractory hypercalcemia with denosumab in a case of metastatic parathyroid carcinoma. J Coll Physicians Surg Pak 2020; 30: 757-759
    CrossrefPubMedSearch in Google Scholar
  • 14 Gill G, Agrawal V, Kerr P. Primary hyperparathyroidism presenting as acute hypercalcemic crisis: a case report. J Otolaryngol Head Neck Surg 2023; 52: 1
    CrossrefPubMedSearch in Google Scholar
  • 15 Jumpertz von Schwartzenberg R, Elbelt U, Ventz M. et al. Palliative treatment of uncontrollable hypercalcemia due to parathyrotoxicosis: denosumab as rescue therapy. Endocrinol Diabetes Metab Case Rep 2015; 2015: 150082
    PubMedSearch in Google Scholar
  • 16 Kuchay MS, Mathew A, Kaur P. et al. Denosumab can be used successfully as a bridge to surgery in patients with severe hypercalcemia due to primary hyperparathyroidism. Arch Endocrinol Metab 2021; 65: 669-673
    PubMedSearch in Google Scholar
  • 17 Lenherr-Taube N, Lam CK, Vali R. et al. Severe primary hyperparathyroidism caused by parathyroid carcinoma in a 13-year-old child; novel findings from HRpQCT. JBMR Plus 2020; 4: e10324
    CrossrefPubMedSearch in Google Scholar
  • 18 Li Y, Fan CY, Manni A. et al. Pitfalls of using denosumab preoperatively to treat refractory severe hypercalcaemia. BMJ Case Rep 2020; 13: e233665
    CrossrefPubMedSearch in Google Scholar
  • 19 Makino H, Notsu M, Asayama I. et al. Successful control of hypercalcemia with sorafenib, evocalcet, and denosumab combination therapy for recurrent parathyroid carcinoma. Intern Med 2022; 61: 3383-3390
    CrossrefPubMedSearch in Google Scholar
  • 20 Omi Y, Yamamoto T, Nagashima Y. et al. Parathyroid carcinoma in a 13-year-old girl with a long-term survival. Surg Case Rep 2020; 6: 145
    CrossrefPubMedSearch in Google Scholar
  • 21 Rajan R, Cherian KE, Kapoor N. et al. Denosumab as a bridge to surgery in a patient with severe hypercalcemia due to primary hyperparathyroidism in the setting of renal dysfunction. Indian J Endocrinol Metab 2019; 23: 269-270
    CrossrefPubMedSearch in Google Scholar
  • 22 Roukain A, Alwan H, Bongiovanni M. et al. Denosumab for the treatment of hypercalcemia in a patient with parathyroid carcinoma: a case report. Front Endocrinol (Lausanne) 2021; 12: 794988
    CrossrefPubMedSearch in Google Scholar
  • 23 Shalaby T, Anandappa S, Sivappriyan S. et al. The use of denosumab in a nonagenarian with primary hyperparathyroidism. Eur Endocrinol 2014; 10: 151-152
    PubMedSearch in Google Scholar
  • 24 Tzotzas T, Goropoulos A, Karras S. et al. Effective long-term management of parathyromatosis-related refractory hypercalcemia with a combination of denosumab and cinacalcet treatment. Hormones (Athens) 2022; 21: 171-176
    CrossrefPubMedSearch in Google Scholar
  • 25 Vellanki P, Lange K, Elaraj D. et al. Denosumab for management of parathyroid carcinoma-mediated hypercalcemia. J Clin Endocrinol Metab 2014; 99: 387-390
    CrossrefPubMedSearch in Google Scholar
  • 26 Kim SY, Ok HG, Birkenmaier C. et al. Can denosumab be a substitute, competitor, or complement to bisphosphonates?. Korean J Pain 2017; 30: 86-92
    CrossrefPubMedSearch in Google Scholar
  • 27 Ahmad S, Kuraganti G, Steenkamp D. Hypercalcemic crisis: a clinical review. Am J Med 2015; 128: 239-245
    CrossrefPubMedSearch in Google Scholar
  • 28 Allgrove J. Biphosphonates. Arch Dis Child 1997; 76: 73-75
    CrossrefPubMedSearch in Google Scholar
  • 29 Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int 2008; 74: 1385-1393
    CrossrefPubMedSearch in Google Scholar
  • 30 Body JJ, Pfister T, Bauss F. Preclinical perspectives on bisphosphonate renal safety. Oncologist 2005; 10: 3-7
    CrossrefPubMedSearch in Google Scholar
  • 31 Chandran M, Bilezikian JP, Lau J. et al. The efficacy and safety of cinacalcet in primary hyperparathyroidism: a systematic review and meta-analysis of randomized controlled trials and cohort studies. Rev Endocr Metab Disord 2022; 23: 485-501
    CrossrefPubMedSearch in Google Scholar
  • 32 Manaka K, Sato J, Kinoshita Y. et al. Effectiveness and safety of cinacalcet for primary hyperparathyroidism: a single center experience. Endocr J 2019; 66: 683-689
    CrossrefPubMedSearch in Google Scholar
  • 33 Peacock M, Bolognese MA, Borofsky M. et al. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J Clin Endocrinol Metab 2009; 94: 4860-4867
    CrossrefPubMedSearch in Google Scholar
  • 34 Raje N, Terpos E, Willenbacher W. et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol 2018; 19: 370-381
    CrossrefPubMedSearch in Google Scholar
  • 35 Bandeira F, Cusano NE, Silva BC. et al. Bone disease in primary hyperparathyroidism. Arq Bras Endocrinol Metabol 2014; 58: 553-561
    CrossrefPubMedSearch in Google Scholar